Digest Network Come funziona
Network
/
Società
Az
Non verificato

Azafaros

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

11 comunicati stampa

Guarda tutti i comunicati
15/06/2026
Eventi
Scienza
Finanza
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Salute
Azafaros to Present at BIO International Convention 2026
Fonte
Azafaros
Emittente
Business Wire
1.00
0
05/06/2026
Scienza
Finanza
Biotecnologia
Medicina - Varie
Associazioni/Professionisti
Salute
Farmaceutica
Industria
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal
Fonte
Azafaros
Emittente
Business Wire
1.00
0
19/05/2026
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer
Fonte
Azafaros
Emittente
Business Wire
1.00
0
25/02/2026
Industria
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Salute
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis
Fonte
Azafaros
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Industria
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference
Fonte
Azafaros
Emittente
Business Wire
1.00
0
11/12/2025
Mercato del lavoro
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Azafaros Further Strengthens Its Board of Directors With Appointment of Biotech Entrepreneur Dr. Thierry Abribat
Fonte
Azafaros
Emittente
Business Wire
1.00
0
28/07/2025
Scienza
Infanzia
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Industria
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
Fonte
Azafaros
Emittente
Business Wire
1.00
0
09/06/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Fiere
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
Fonte
Azafaros
Emittente
Business Wire
1.00
0
13/05/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Finanza
Sanità
Salute
Associazioni/Professionisti
Medicina - Varie
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders
Fonte
Azafaros
Emittente
Business Wire
1.00
0
09/01/2025
Eventi
Industria
Biotecnologia
Farmaceutica
Medicina alternativa
Salute
Igiene alimentare
Medicina - Varie
Sanità
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Fonte
Azafaros
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0